The European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) recommended the granting of ...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary ...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows posit ...

Diabetic Macular Edema Market valuation is set to cross USD 4,642.9 million by 2034, at a CAGR of 1.2% through 2034.

Bowers added that to increase access to the latest drugs, the "cancer system" must be organized in such a way as to ...

At the turn of the millennium the four largest firms in the average European industry claimed a market share of less than 26% ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...

Data demonstrated statistically significant and clinically meaningful reduction in risk of disease progression or death with Cabometyx® ...

Data demonstrated statistically significant and clinically meaningful reduction in risk of disease progression or death with Cabometyx® (cabozantinib) versus placebo in advanced pancreatic and extra-p ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed amivantamab combined with chemotherapy (mFOLFOX6 [FOLFOX] or ...